Clinical Trial Update: A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating lazertinib in EGFR mutation–positive advanced non-small cell lung cancer has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-28